Janney Montgomery Scott Upgrades Sarepta Therapeutic (SRPT) to Buy

Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer

Oppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).

Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate... More

Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush

Wedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $66.00 (from $36.00) after the FDA approved eteplirsen.

Behanna commented, "In line with our expectations after FDA asked for new data, eteplirsen has received accelerated... More

RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target

RBC Capital upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Sector Perform to Outperform with a price target of $83.00 (from $5.00).

Analyst Simos Simeonidis commented, "In one of the most perplexing regulatory decisions in recent history, FDA has granted accelerated approval to Sarepta's eteplirsen.... More

Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & Company

Needham & Company analyst Chad Messer reiterated a Buy rating and raised his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $81.00 (from $47.00) following eteplirsen approval.

Messer commented, "The FDA has granted conditional approval to eteplirsen (Exondys 51) stating that data on dystrophin production was "reasonably... More

Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market Perform

Leerink Partners upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Underperform to Market Perform with a price target of $50.00 (from $5.00).

Analyst Joseph Schwartz commented, "Sarepta's eteplirsen (Exondys 51, Duchenne Muscular Dystrophy) surprisingly received FDA's accelerated approval (AA), in stark contrast to the FDA's negative commentary... More

Sarepta (SRPT) PT Raised to $76 at Oppenheimer Amid Eteplirsen Approval

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and raised her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $76.00 (from $60.00) after the FDA announced the approval of eteplirsen (EXONDYS 51) for the treatment of all boys with DMD amenable to Exon 51 skipping.

Gilson... More

Sarepta Therapeutics (SRPT) Pushes to Highs Following FDA Approval; +90%

Sarepta Therapeutics (NASDAQ: SRPT) trading at the highs of the session following FDA approval. Shares are up 90.7%

FDA Approves Sarepta Therapeutics' (SRPT) Eteplirsen

(Updated - September 19, 2016 9:56 AM EDT)

The U.S. Food and Drug Administration today approved Sarepta Therapeutics' (Nasdaq: SRPT) Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD.

Patients with a particular type of Duchenne muscular dystrophy will now have access to an approved treatment for this rare and devastating disease, said Janet Woodcock, M.D., director of the... More

Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for Eteplirsen

Sarepta Therapeutics (NASDAQ: SRPT) surges higher on FDA approval for eteplirsen

Letter from FDA